(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...
AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results